Biohaven initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao initiated coverage of Biohaven with a Buy rating and $50 price target. The company is well positioned with a pipeline with three potential blockbuster platforms that seek to replicate the success of legacy Biohaven’s migraine franchise, the analyst tells investors in a research note. Given the upside potential for each of the company’s platforms, along with management’s track record of value creation, it is “worth getting involved since inflection in value could occur quickly,” says the firm.